US FDA Hoping To Spur More ANDA Pre-Submission Meetings During GDUFA III
Executive Summary
The FDA believes conducting a pre-submission meeting when a complex generic application has unusual elements can increase the likelihood of a first-cycle approval.
You may also be interested in...
Generic Drug Facility Post-Warning Letter Meetings Likely Will Hinge On ‘Reasonable Progress’
Facility owners should ensure they are ready when asking for the meeting on deficiency remediation because only two requests are allowed per warning letter.
US FDA Seeks Ability To Include More Inactive Ingredient, Excipient Info In Brand Labeling
Additions could help streamline generic development, Center for Drug Evaluation and Research Director Patrizia Cavazzoni says.
Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes
A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.